<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02629796</url>
  </required_header>
  <id_info>
    <org_study_id>AGN_2013-9</org_study_id>
    <nct_id>NCT02629796</nct_id>
  </id_info>
  <brief_title>Biomark Study: Predict Intravenous Immunoglobulin Responders in Chronic Inflammatory Demyelinating Polyradiculoneuropathy</brief_title>
  <acronym>BIOMARK</acronym>
  <official_title>Biomarker to Predict the Response to Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients: a Transcriptomic Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <brief_summary>
    <textblock>
      This study aims analyze the transcriptome to identify predictive biomarkers of IVIG in CIDP
      patients. 25 patients with a diagnosis of CIDP according to European criteria, naïve of
      treatment, will be included and followed for 1 year. Clinical assessment (RT-MRC ; Martin
      vigorimeter, RT-mISS,R-ODS,TW25, 9hole-peg test) will be performed at baseline and at 3, 6
      and 12 months after the first IVIG course. Responder/No responder status will be defined at 3
      month and confirmed at 12 months. Blood samples will be collected before the IVIG course at
      baseline, and at 2months and 6 months. At the end of the first IVIG course a blood sample
      will be collected to assess early changes of transcriptome. The CIDP diagnosis and
      responder/no responder status will be confirmed by an independent committee. The
      transcriptome of the patients will be individually analyzed and compared regarding
      Responder/Non responder status to a control groups of 20 healthy subjects
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>blood-levels of biomarkers of Intravenous immunoglobulin response</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">45</enrollment>
  <condition>CIDP</condition>
  <arm_group>
    <arm_group_label>CIDP treated (IVIG)</arm_group_label>
    <description>patients with a diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) according to European criteria, treated with IVIG (intravenous immunoglobulin as a first line of treatment) as a usual treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <description>healthy subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CIDP treated (IVIG)</intervention_name>
    <description>usual treatment with intravenous immunoglobulin</description>
    <arm_group_label>CIDP treated (IVIG)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with chronic inflammatory demyelinating polyradiculoneuropathy. Transcriptome,
        metabolome and proteome analysis compared with those of healthy subjects
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  chronic inflammatory demyelinating polyradiculoneuropathy (according to european
             criterions)

          -  first line of treatment

          -  treatment with intravenous immunoglobulin required

          -  healthy subjects matched for age and gender

        Exclusion Criteria:

        For CIDP patients

          -  uncontrolled diabetes, monoclonal spike with anti-ganglioside activity, anti
             myelin-associated glycoprotein antibodies, HIV infection, HBV infection, HCV
             infection, connective tissue disease, hemopathy, evolutive disease)

        For healthy subjects:

        any chronic or autoimmune disease

        For all subjets viral or bacterial infection in the last 30 days chemotherapy in the last 5
        years immunosuppressive therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Antoine GUEGUEN, MD</last_name>
    <email>agueguen@fo-rothschild.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Bordeaux, service de Neurologie</name>
      <address>
        <city>Bordeaux</city>
        <state>Aquitaine</state>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guilhem SOLE, MD</last_name>
      <email>guilhem.sole@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <state>Ile De France</state>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain CREANGE, MD</last_name>
      <email>alain.creange@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nantes, Laboratoire d'explorations fonctionnelles</name>
      <address>
        <city>Nantes</city>
        <state>Loire Atlantique</state>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armelle MAGOT, MD</last_name>
      <email>armelle.magot@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Steeve GENESTET, MD</last_name>
      <email>steeve.genestet@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de CAEN</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathilde LEFILLIATRE, MD</last_name>
      <email>lefilliatre-m@chu-caen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Celine TARD, MD</last_name>
      <email>celinetardpro@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Neurologie, CHU Limoges,</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Magy, MD</last_name>
      <email>laurent.magy@unilim.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Neurologique HCL, Lyon-Bron</name>
      <address>
        <city>Lyon</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe VIAL, MD</last_name>
      <email>christophe.vial@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de NIMES</name>
      <address>
        <city>Nimes</city>
        <zip>30900</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Astrid COLORBE, MD</last_name>
      <email>astrid.colorbe@chu-nimes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Physiologie Clinique - Explorations Fonctionnelles, Hôpital Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre LOZERON, MD</last_name>
      <email>pierre.lozeron@lrb.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Neurologie, Fondation Ophtalmologique Adolphe de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine Gueguen, MD</last_name>
      <phone>+33143086755</phone>
      <email>agueguen@fo-rothschild.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Poissy/Saint-Germain-en-Laye</name>
      <address>
        <city>Poissy</city>
        <zip>78303</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier HEINZLEF, MD</last_name>
      <email>oheinzlef@chi-poissy-st-germain.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan CIRON, MD</last_name>
      <email>jonathan.ciron@chu-poitiers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de ROUEN</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Laure MILLET, MD</last_name>
      <email>anne-laure.millet@chu-rouen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Saint-Denis</name>
      <address>
        <city>Saint-Denis</city>
        <zip>93205</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne LAZAR, MD</last_name>
      <email>anne.lazar@ch-stdenis.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Neurologie CHU St Etienne</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Philippe Camdessanche, MD</last_name>
      <phone>+33477127805</phone>
      <email>j.philippe.camdessanche@chu-st-etienne.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Neurologie, CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andoni ECHANIZ-LAGUNA, MD</last_name>
      <email>andoni.echaniz-laguna@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2015</study_first_submitted>
  <study_first_submitted_qc>December 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2015</study_first_posted>
  <last_update_submitted>November 21, 2017</last_update_submitted>
  <last_update_submitted_qc>November 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Biomarker</keyword>
  <keyword>CIDP</keyword>
  <keyword>IVIG</keyword>
  <keyword>treatment response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyradiculoneuropathy</mesh_term>
    <mesh_term>Polyradiculoneuropathy, Chronic Inflammatory Demyelinating</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

